Patents by Inventor Pamela T. Manning
Pamela T. Manning has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11692035Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: GrantFiled: December 4, 2019Date of Patent: July 4, 2023Assignee: Arch Oncology, Inc.Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
-
Publication number: 20230192849Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.Type: ApplicationFiled: October 27, 2022Publication date: June 22, 2023Inventors: William A. FRAZIER, Pamela T. MANNING, Gerhard FREY, Hwai Wen CHANG, Robert W. KARR
-
Publication number: 20220313819Abstract: Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, which include but are not limited to proteasome inhibitors, immunomodulatory agents, Bruton's tyrosine kinase (BTK) inhibitors, BCMA-targeting agents, CAR-T cells, anthracyclines, platinums, taxols, cyclophosphamides, topoisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, alkylating agents, and demethylating agents.Type: ApplicationFiled: April 22, 2022Publication date: October 6, 2022Inventors: Michael DONIO, Pamela T. MANNING, Robyn PURO, Juan C. ALMAGRO, Robert W. KARR, Benjamin J. CAPOCCIA, Myriam BOUCHLAKA, W. Casey WILSON, Daniel S. PEREIRA
-
Patent number: 11292834Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemic-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.Type: GrantFiled: February 28, 2019Date of Patent: April 5, 2022Assignee: Arch Oncology, Inc.Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang, Robert W. Karr
-
Publication number: 20210395831Abstract: Provided are methods for treatment of cancer. Also provided are methods for treating a patient susceptible, or suspected of being susceptible, with anti-CD47 therapy.Type: ApplicationFiled: November 8, 2019Publication date: December 23, 2021Inventors: Benjamin J. CAPOCCIA, Robyn PURO, W. Casey WILSON, Pamela T. MANNING, Robert W. KARR
-
Publication number: 20210324075Abstract: Provided are murine, chimeric, and humanized anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles, methods to generate anti-CD47 mAbs, and methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases, and as diagnostics for determining the level of CD47 in tissue samples.Type: ApplicationFiled: August 13, 2019Publication date: October 21, 2021Inventors: Robyn PURO, Pamela T. MANNING, Robert W. KARR, Juan C. ALMAGRO
-
Publication number: 20210079091Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: ApplicationFiled: July 29, 2020Publication date: March 18, 2021Inventors: Pamela T. MANNING, Robyn PURO, Juan C. ALMAGRO, Robert W. KARR
-
Publication number: 20210070865Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: ApplicationFiled: October 29, 2020Publication date: March 11, 2021Inventors: Pamela T. MANNING, Robyn PURO, Juan C. ALMAGRO, Robert W. KARR
-
Patent number: 10844124Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: GrantFiled: February 8, 2019Date of Patent: November 24, 2020Assignee: Arch Oncology, Inc.Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
-
Publication number: 20200297842Abstract: Anti-SIRP? monoclonal antibodies (anti-SIRP? mAbs), including multispecific SIRP? antibodies, are provided with distinct functional profiles as are related compositions and methods of using anti-SIRP? mAbs as therapeutics for the prevention and treatment of solid and hematological cancers. Also provided are amino acid sequences of exemplary anti-SIRP? monoclonal antibodies.Type: ApplicationFiled: November 13, 2019Publication date: September 24, 2020Inventors: Robyn PURO, Pamela T. MANNING, Robert W. KARR, Ronald R. HIEBSCH, Benjamin J. CAPOCCIA, Gabriela ANDREJEVA
-
Patent number: 10676524Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.Type: GrantFiled: October 3, 2017Date of Patent: June 9, 2020Assignee: Arch Oncology, Inc.Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
-
Patent number: 10669336Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.Type: GrantFiled: October 3, 2017Date of Patent: June 2, 2020Assignee: Arch Oncology, Inc.Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
-
Publication number: 20200095318Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: ApplicationFiled: December 4, 2019Publication date: March 26, 2020Inventors: Pamela T. MANNING, Robyn PURO, Juan C. ALMAGRO, Robert W. KARR
-
Publication number: 20190309066Abstract: Methods are provided for using anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, with other anti-cancer agents, which include but are not limited to proteasome inhibitors, anthracyclines, platinums, taxols, topisomerase inhibitors, anti-metabolites, anti-tumor antibiotics, mitotic inhibitors, and alkylating agents.Type: ApplicationFiled: June 25, 2019Publication date: October 10, 2019Inventors: Pamela T. MANNING, Robyn PURO, Juan C. ALMAGRO, Robert W. KARR, Benjamin J. CAPOCCIA
-
Publication number: 20190300611Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: ApplicationFiled: February 8, 2019Publication date: October 3, 2019Inventors: Pamela T. MANNING, Robyn PURO, Juan C. ALMAGRO, Robert W. KARR
-
Publication number: 20190248892Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemic-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.Type: ApplicationFiled: February 28, 2019Publication date: August 15, 2019Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
-
Publication number: 20190112373Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: ApplicationFiled: December 17, 2018Publication date: April 18, 2019Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
-
Patent number: 10259873Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.Type: GrantFiled: November 8, 2016Date of Patent: April 16, 2019Assignee: Arch Oncology, Inc.Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
-
Patent number: 10239945Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: GrantFiled: November 21, 2017Date of Patent: March 26, 2019Assignee: Arch Oncology, Inc.Inventors: Pamela T. Manning, Robyn Puro, Juan C. Almagro, Robert W. Karr
-
Publication number: 20180171014Abstract: Provided are anti-CD47 monoclonal antibodies (anti-CD47 mAbs) with distinct functional profiles as described herein, methods to generate anti-CD47 mAbs, and to methods of using these anti-CD47 mAbs as therapeutics for the prevention and treatment of solid and hematological cancers, ischemia-reperfusion injury, cardiovascular diseases, autoimmune diseases, inflammatory diseases or as diagnostics for determining the level of CD47 in tissue samples.Type: ApplicationFiled: November 21, 2017Publication date: June 21, 2018Inventors: Pamela T. MANNING, Robyn PURO, Juan C. ALMAGRO, Robert W. KARR